Patents by Inventor Ulf BRASEN

Ulf BRASEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dextran sulfate
    Patent number: 10730960
    Abstract: Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (Mn) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da; an average sulfate number per glucose unit within an interval of 2.5 and 3.0; and an average sulfation of C2 position in the glucose units of said dextran sulfate of at least 90%, or a salt of such a dextran sulfate.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: August 4, 2020
    Assignee: TX MEDIC AB
    Inventors: Lars Bruce, Ulf Brasen
  • DEXTRAN SULFATE
    Publication number: 20190375859
    Abstract: Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (Mn) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da; an average sulfate number per glucose unit within an interval of 2.5 and 3.0; and an average sulfation of C2 position in the glucose units of said dextran sulfate of at least 90%, or a salt of such a dextran sulfate.
    Type: Application
    Filed: July 24, 2019
    Publication date: December 12, 2019
    Inventors: Lars BRUCE, Ulf BRASEN
  • Dextran sulfate
    Patent number: 10407514
    Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: September 10, 2019
    Assignee: TX MEDIC AB
    Inventors: Lars Bruce, Ulf Brasen
  • NEW DEXTRAN SULFATE
    Publication number: 20180298116
    Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.
    Type: Application
    Filed: November 10, 2015
    Publication date: October 18, 2018
    Inventors: Lars BRUCE, Ulf BRASEN